Adial Pharmaceuticals, Inc. (ADIL) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Charlottesville, VA, 美国. 现任CEO为 Cary John Claiborne.
ADIL 拥有 IPO日期为 2018-07-27, 5 名全职员工, 在 NASDAQ Capital Marke, 市值为 $1.55M.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
